ロード中...
Stable Dry Powder Formulation for Nasal Delivery of Anthrax Vaccine
There is a current biodefense interest in protection against Anthrax. Here we developed a new generation of stable and effective anthrax vaccine. We studied the immune response elicited by rPA delivered intranasally with a novel mucosal adjuvant, a mast cell activator Compound 48/80. The vaccine for...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2011
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3725471/ https://ncbi.nlm.nih.gov/pubmed/21905034 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jps.22742 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|